Patrick Waller

Summary

Country: UK

Publications

  1. ncbi Drug safety and the media
    Patrick C Waller
    Br J Clin Pharmacol 61:123-6. 2006
  2. ncbi European commission consultation on pharmacovigilance
    Patrick Waller
    Pharmacoepidemiol Drug Saf 17:108-9. 2008
  3. ncbi Developing tools for the safety specification in risk management plans: lessons learned from a pilot project
    Andrew J P Cooper
    GlaxoSmithKline GSK Ltd, Greenford, Middlesex, UK
    Pharmacoepidemiol Drug Saf 17:445-54. 2008
  4. ncbi A model for the future conduct of pharmacovigilance
    Patrick C Waller
    Post Licensing Division, Medicines Control Agency, London, UK
    Pharmacoepidemiol Drug Saf 12:17-29. 2003
  5. ncbi Making the most of spontaneous adverse drug reaction reporting
    Patrick C Waller
    Consultant in Pharmacoepidemiology, Southampton, UK
    Basic Clin Pharmacol Toxicol 98:320-3. 2006
  6. ncbi Impact analysis of signals detected from spontaneous adverse drug reaction reporting data
    Patrick Waller
    Patrick Waller Limited, Consultancy in Pharmacovigilance and Pharmacoepidemiology, Southampton, UK
    Drug Saf 28:843-50. 2005
  7. ncbi Hospital admissions for 'drug-induced' disorders in England: a study using the Hospital Episodes Statistics (HES) database
    Patrick Waller
    Drug Safety Research Unit, Southampton, UK
    Br J Clin Pharmacol 59:213-9. 2005
  8. ncbi Dealing with uncertainty in drug safety: lessons for the future from sertindole
    Patrick Waller
    Pharmacoepidemiol Drug Saf 12:283-7; discussion 289-90. 2003
  9. ncbi Comparison of hospital episodes with 'drug-induced' disorders and spontaneously reported adverse drug reactions
    Paul Barrow
    Post Licensing Division, Medicines and Healthcare products Regulatory Agency, London, UK
    Br J Clin Pharmacol 61:233-7. 2006
  10. ncbi Testing and implementing signal impact analysis in a regulatory setting: results of a pilot study
    Emma Heeley
    Post Licensing Division, Medicines and Healthcare products Regulatory Agency, London, UK
    Drug Saf 28:901-6. 2005

Collaborators

Detail Information

Publications12

  1. ncbi Drug safety and the media
    Patrick C Waller
    Br J Clin Pharmacol 61:123-6. 2006
    ..In order to promote more balanced coverage and avoid unnecessary scares, professionals working in the area of drug safety should rethink their strategies for dealing with the media...
  2. ncbi European commission consultation on pharmacovigilance
    Patrick Waller
    Pharmacoepidemiol Drug Saf 17:108-9. 2008
  3. ncbi Developing tools for the safety specification in risk management plans: lessons learned from a pilot project
    Andrew J P Cooper
    GlaxoSmithKline GSK Ltd, Greenford, Middlesex, UK
    Pharmacoepidemiol Drug Saf 17:445-54. 2008
    ..A collaborative research project was conducted to gain experience with tools for presenting and evaluating data in the safety specification. This paper presents those tools found to be useful and the lessons learned from their use...
  4. ncbi A model for the future conduct of pharmacovigilance
    Patrick C Waller
    Post Licensing Division, Medicines Control Agency, London, UK
    Pharmacoepidemiol Drug Saf 12:17-29. 2003
    ..Although the vision is holistic, it would be possible to test and implement parts of the model in a piecemeal fashion...
  5. ncbi Making the most of spontaneous adverse drug reaction reporting
    Patrick C Waller
    Consultant in Pharmacoepidemiology, Southampton, UK
    Basic Clin Pharmacol Toxicol 98:320-3. 2006
    ..However much it can be improved, spontaneous adverse drug reaction reporting is unlikely to identify all important unrecognized drug safety hazards. Complementary approaches therefore still need to be identified and developed...
  6. ncbi Impact analysis of signals detected from spontaneous adverse drug reaction reporting data
    Patrick Waller
    Patrick Waller Limited, Consultancy in Pharmacovigilance and Pharmacoepidemiology, Southampton, UK
    Drug Saf 28:843-50. 2005
    ..A computer program has been written to facilitate the process and reduce error. Further work is required to test the feasibility and value of impact analysis in practice...
  7. ncbi Hospital admissions for 'drug-induced' disorders in England: a study using the Hospital Episodes Statistics (HES) database
    Patrick Waller
    Drug Safety Research Unit, Southampton, UK
    Br J Clin Pharmacol 59:213-9. 2005
    ....
  8. ncbi Dealing with uncertainty in drug safety: lessons for the future from sertindole
    Patrick Waller
    Pharmacoepidemiol Drug Saf 12:283-7; discussion 289-90. 2003
  9. ncbi Comparison of hospital episodes with 'drug-induced' disorders and spontaneously reported adverse drug reactions
    Paul Barrow
    Post Licensing Division, Medicines and Healthcare products Regulatory Agency, London, UK
    Br J Clin Pharmacol 61:233-7. 2006
    ..To compare Hospital Episode Statistics for 'drug-related' admissions with spontaneously reported adverse drug reactions (ADRs) using UK Yellow Card data for the period 1996-2000...
  10. ncbi Testing and implementing signal impact analysis in a regulatory setting: results of a pilot study
    Emma Heeley
    Post Licensing Division, Medicines and Healthcare products Regulatory Agency, London, UK
    Drug Saf 28:901-6. 2005
    ..This paper describes a pilot project whereby impact analysis was simultaneously introduced into practice in a regulatory setting and tested in comparison with the existing approach...
  11. ncbi An analysis of the exclusion criteria used in observational pharmacoepidemiological studies
    Michael Perrio
    Drug Safety Research Unit, Southampton, UK
    Pharmacoepidemiol Drug Saf 16:329-36. 2007
    ..The application of exclusion criteria in pharmacoepidemiological studies could have a major impact on the findings but there appears to have been no previous research to examine the types of exclusion criteria applied...
  12. ncbi Drug safety and regulation
    Patrick C Waller
    BMJ 331:4-5. 2005